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Methotrexate (MTX) is an important cytostatic drug in can-
cer chemotherapy and the most widely used antimetabolite
in childhood cancers. It is effective in the treatment of acute
lymphoblastic leukemia (ALL), non-Hodgkin lymphoma, histi-
ocytosis and osteosarcoma. Although its mechanism of action
is not fully understood, it had been postulated as a cell cycle
speciﬁc folate that inhibits dihydrofolate reductase achieving
elevated levels of homocysteine and excitatory amino acid
neurotransmitter metabolites.
High dose MTX  (HDMTX) is commonly used in the treat-
ment of osteosarcoma.1 It can cause acute, subacute and
chronic neurological complications. Stroke-like encephalo-
pathy is a sub-acute MTX  neurotoxicity and a rare syndrome
that manifests with an abrupt onset of focal neurological
deﬁcits.2 It can cause hemiparesis, slurred speech, confusion,
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The symptoms presented by children usually occur days to
weeks after MTX administration and resolve over hours to
days, without permanent neurological sequelae.2,4
We  describe the neuroimaging features of a male teenage
patient with osteosarcoma who presented with anxiety, con-
fusion and emotional liability characterizing an episode of
sub-acute transient cerebral dysfunction associated with
alternating hemiparesis 12 days after receiving intravenous
HDMTX (12 g/m2). Imaging within 24 h of symptom onset
showed bilateral symmetrical restricted diffusion involv-
ing white matter of the cerebral hemispheres. Computed
tomography (CT), magnetic resonance imaging (MRI) and), Hospital das Clínicas, Avenida Alfredo Balena, n◦ 110, 30130-100
angiography showed no evidence of vasospasm or perfusion
defects. MRI 30 days after ﬁrst abnormality evidenced com-
plete resolution and no signal was seen on T2 or ﬂuid
attenuated inversion recovery (FLAIR).
 e Terapia Celular. Published by Elsevier Editora Ltda. This is an
mons.org/licenses/by-nc-nd/4.0/).
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Figure 1 – (A) Diffusion weighted imaging (DWI): symmetrical hyperintense signal in parietal lobe white matter, neither
cortical area nor deep gray matter structures were affected. (B) Decreased apparent diffusion coefﬁcient (ADC): symmetrical
hyperintense signal. (C) Axial T2/FLAIR image: discreet symmetrical hyperintense signal in parietal lobe white matter. (D)
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ase  presentation
 15-year-old boy diagnosed with osteosarcoma of the right
istal tibia and pulmonary metastasis initiated neoadjuvant
hemotherapy with cisplatin (60 mg/m2/day for two days) and
oxorrubicyn (37.5 mg/m2/day for two days) alternating with
DMTX (12 g/m2) in a six-week cycle. Leucovorin rescue (15 mg
ach six hours) was started 24 h after the end of every cycle of
he HDMTX infusion until safe MTX  plasma concentrations
ad been reached. Toxic levels were not observed.
The monitoring of MTX  plasma levels after the fourth cycle
howed concentrations of 6.26 mol/L at 24 h, 0.78 mol/L at
8 h and at 0.13 mol/L at 72 h. Twelve days after this cycle, he
resented psychomotor agitation, violent and bizarre behav-
or but preserved comprehension of time and space. His vital
igns were stable. He was administered anxiety medications
clonazepam) and oxygen by facemask and the symptoms
radually resolved.
Subsequently, an abrupt onset of left-sided upper and lower
imb paresthesia with ipsilateral hyporeﬂexia was observedbe. No abnormality was observed in T1.
without involvement of the face. An urgent brain CT scan
did not show any evidence of vascular abnormalities to sug-
gest vasospasm or hemorrhage. Additional hematological,
viral serology, cerebrospinal ﬂuid and blood chemistry (renal
and liver functions and serum electrolytes) laboratory exams
were performed with none identifying any abnormalities. Five
hours after the beginning of neurological abnormalities, a
physical examination of the patient was normal and there
were no further complaints.
The following day, the patient complained of right-sided
hemiparesis without reﬂexes of upper and lower limbs, but
with mental status and vital signs being stable.
Gadolinium-enhanced MRI of the brain was performed and
showed symmetrical hyperintense diffusion-weighted imag-
ing (DWI) signals and decreased apparent diffusion coefﬁcient
(ADC) in the parietal lobe white matter, more  prominent on
the left side, however neither the cortical area nor deep gray
matter structures were affected. There was no signal change
on FLAIR and T2 images. No abnormality was observed in T1
images (Figure 1). Dynamic susceptibility perfusion imaging
showed no evidence of abnormal mean transit time, cerebral
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Figure 2 – Magnetic resonance imaging (MRI) of the brain 30 days after onset with no abnormal ﬁndings. (A) Diffusion
weighted imaging (DWI). (B) Axial T2/FLAIR image. (C) Axial T2.blood ﬂow or cerebral blood volume. The absence of vascular
or perfusion abnormalities suggests that transient cytotoxic
edema of the white matter may be explained by MTX-induced
stroke-like encephalopathy.4,5
The patient recovered movements within 48 h; however,
ataxic gait disappeared only after eight days of follow-up.
Further MRI  scans of the brain 30 days after onset showed
no abnormal ﬁndings on FLAIR, T2 and diffusion weight
images (Figure 2) and the patient continued to be neurolog-
ically asymptomatic.
Discussion
Stroke-like encephalopathy is a rare MTX  neurotoxicity that
manifests with sudden onset of focal neurological deﬁcits,
such as hemiparesis, that occur days to weeks after MTX
administration. Neurological symptoms recover completely
over hours to days and no residual deﬁcit nor intellectual
impairment are identiﬁed during clinical follow-ups over a
two-year period.2,6
In a recent study, 3.8% of all patients who received MTX
developed a related sub-acute neurotoxic event. Neurotoxic
events were identiﬁed by MRI  in 20.6% of asymptomatic
patients and in all symptomatic patients.7
High doses of MTX  (1.5–8 g/m2) and age over 10 years were
associated with stroke-like encephalopathy in children with
acute lymphoblastic leukemia. Headache, confusion, disori-
entation, seizure, and focal neurologic deﬁcits were described
as the ﬁrst manifestations.4,8,9
The pathophysiological mechanism of this syndrome is not
well understood, but it is likely to be multifactorial. Authors
have suggested that possible mechanisms of MTX neurotoxic-
ity such as chronic folate depletion in brain tissue, increased
excitatory amino acids, excess homocysteine and alterations
of biopterin and adenosine metabolisms may reduce neuro-
transmitter synthesis.10
MTX  promotes release of adenosine from ﬁbroblast and
endothelial cells, elevating adenosine levels, which dilate
cerebral blood vessels, modify the release of presynaptic andpostsynaptic neurotransmitters and may slow discharge rate
of neurons.4,10–12
Conventional CT scans, MRI and angiography have not
showed a pattern of consistent abnormalities to characterize
MTX neurotoxicity.4
Stroke-like encephalopathy associated with MTX  neu-
rotoxicity can be diagnosed when MRI comprise transient
symmetrical T2-weighted signal hyperintensity in the sub-
cortical and periventricular white matter. Usually there is
resolution of restricted diffusion on follow-up MRI.2,4,13
This patient’s MRI  showed transient symmetrical restricted
diffusion in the cerebral white matter and no evidence of
vasospasm or perfusion deﬁcit. Four weeks later, there were no
residual abnormalities. The radiographic ﬁndings of transient
restricted diffusion without vascular or perfusion changes are
consistent with reversible cytotoxic edema involving the white
matter of both hemispheres.
Patients with higher risk for neurotoxic events are those
older than ten years and with high-risk cancer. Higher MTX
levels at 48 h and higher homocysteine concentrations were
associated with increased risk of leukoencephalopathy.7
Despite multiple candidate-gene studies for toxicity,
results are conﬂicting. It has been shown that single-
nucleotide polymorphisms inﬂuence the risk of leukoen-
cephalopathy and symptomatic neurotoxicity although these
ﬁndings were not replicated. Inherited genomic variations are
associated with HDMTX clearance and toxicity is associated
with a polymorphism of the Solute Carrier Organic Anion Trans-
porter Family Member 1B1 (SLCO1B1) gene, which encodes a
hepatic solute carrier organic transporter that mediates med-
ications such as MTX.7,14,15
Although this event cannot be predicted, an early detection
of MTX white matter injury in imaging exams can warn onco-
logists and neurologists about this event. Since MTX  is widely
used, the challenge of this report was to alert physicians about
the diagnosis and ﬁnal outcome of MTX neurotoxicity. Reports
of neuropsychologic dysfunction after HDMTX therapy are
still scarce. The mechanism for MTX-mediated neurotoxic-
ity is not clear and a multifactorial etiology seems to be the
cause. Chronic folate depletion of brain tissue, relative homo-
cysteine excess with increased excitatory amino acids, and
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s possible mechanisms for some forms of acute or chronic
eurotoxicity.16
As stroke-like encephalopathy is generally benign, tran-
ient and does not recur, this event should not preclude
urther use of this chemotherapeutic agent. Despite the lim-
tations of an analysis of isolated experience, these data
ighlight the necessity of studies addressing the pathophysi-
logy mechanisms of MTX  neurotoxicity, its incidence and the
evelopment of preventive measures.
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